Two Sigma Ventures

Two Sigma Ventures is the venture arm of Two Sigma Investments, the New York-headquartered quantitative hedge fund that manages over $60 billion across systematic trading strategies. Two Sigma Ventures was launched as a separate venture franchise to invest in data-driven companies that can leverage Two Sigma’s unique technical infrastructure, including a network of more than 1,600 data scientists and engineers. The firm announced its third fund of $288 million in 2020 and has continued to deploy capital across enterprise AI, fintech, robotics, retail tech, and a meaningful slice of healthcare and biotech, all under a thesis that emphasizes data leverage, machine learning, and AI as the defining wedge for next-generation companies.

The team is led by managing partners and partners drawn from Two Sigma’s quantitative research teams, prior venture funds, and operating roles at technology and data companies. Colin Beirne is among the senior partners and has been a long-tenured voice in the firm’s investment strategy. Dusan Perovic, a partner at Two Sigma Ventures, directs investing at the intersection of life sciences and data science and has been the public face of the firm’s healthcare and biotech practice. The broader team includes partners and principals across enterprise software, AI infrastructure, robotics, and consumer-tech categories, and the firm’s distinctive operational asset is its access to Two Sigma’s quantitative engineering bench and proprietary infrastructure for data-driven companies.

The healthcare and biotech portfolio is curated rather than expansive, reflecting the firm’s thesis of 8 to 10 core early-stage investments per year across categories. Notable healthcare and life sciences investments include Carbon Health, the technology-driven primary care provider; Insitro, the machine-learning-driven drug discovery company founded by Daphne Koller; and WHOOP, the wearable performance and physiological monitoring platform. The firm has historically been active in companies that combine AI and machine learning with healthcare workflows, life sciences research, and tech-enabled care delivery, with a clear preference for technical founders building defensible data-driven platforms.

Check sizes run from $3 million at seed up to $20 million at Series B, with the capacity to lead at seed and Series A and to follow on into later rounds. The firm leads and co-leads at early stages and is comfortable participating in syndicates with peer specialists at Series B and beyond. Geographic scope is US with selective European and Israeli deals, and a strong network density in New York, San Francisco, Boston, and London.

Founders who should approach Two Sigma Ventures are technical AI and machine learning founders building data-driven healthcare and life sciences platforms with a defensible data moat or computational advantage. The firm is particularly well suited for founders coming out of quantitative or technical research backgrounds and for operators who want a venture partner with substantial engineering and data science depth. Founders building therapeutics-only companies, pure DTC consumer health, or healthcare services without a clear data or AI wedge should pitch other firms. Two Sigma Ventures is decisively a data-and-AI-first firm; its bar is technical, not commercial.

Entry path runs through warm introductions from portfolio CEOs, peer AI and data investors, and the broader Two Sigma operating network. The senior team is at major AI and venture conferences in the Bay Area and New York, plus selectively at JPMorgan Healthcare, BIO, and the AI research conferences when the focus is computational drug discovery or healthcare AI. Cold inbound through the website is triaged. Diligence is rigorous on the technical side, often including engagement from Two Sigma’s broader data science and engineering bench, typically three to six weeks from first meeting to term sheet.

In a pitch, lead with the technical wedge, the data, and the AI thesis. Two Sigma Ventures partners are quantitatively trained and want to see why your model architecture, your data acquisition strategy, or your computational approach yields a defensible advantage. Bring rigor, a clear plan to translate computational advantage into a product or platform, and a credible answer to why incumbents and competitors cannot easily replicate your work. The firm’s added value is most powerful when founders use the broader Two Sigma platform: access to the firm’s engineering and data science network, technical advisory across machine learning and AI infrastructure, and connections to peer technical investors. Founders building data-and-AI-first healthcare and life sciences platforms will find Two Sigma Ventures one of the more rigorous and technically engaged tier-one early-stage partners in the category.